Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans

October 1, 2020 updated by: VA Office of Research and Development
This study is intended to test the influence of weight training on physical symptoms, physical activity and brain structure and function in Gulf War Veterans with chronic widespread muscle pain.

Study Overview

Status

Completed

Detailed Description

Musculoskeletal pain in soldiers who returned from the Persian Gulf War is a serious problem. Numerous studies have reported musculoskeletal pain as a primary symptom of sick Gulf Veterans (GVs), with ~100,000 Veterans (~15%) reporting unresolved pain affecting their social and professional lives. Pain and other symptoms are often disabling with 1 in 7 United States Veterans seeking care for war-related health concerns and ~12% receiving disability compensation. Thus, a significant number of military personnel are no longer able to perform their duties due to medically unexplained symptoms including pain, fatigue and cognitive problems. Importantly, recent evidence suggests that chronic pain complaints in most GVs have not resolved. Similar problems appear to be on the horizon for Veterans from Operations Enduring and Iraqi Freedom. Understanding the pathophysiological consequences of chronic muscle pain is important for better determining both the efficacy and mechanism of treatments aimed at decreasing debilitating symptoms and improving physical function among Veterans coping with chronic pain.

Given the dearth of experimental data in GVs with chronic musculoskeletal pain (CMP), we have patterned much of our research in GVs after our research in fibromyalgia (FM), a disorder with a primary symptom of muscle and joint pain in civilians. Our work and the work of others suggest that FM pain is produced and maintained by central nervous system (CNS) dysregulation of nociceptive and pain processes. Our work also suggests that phenomena similar to those observed in FM may be occurring in GVs with CMP. Like FM patients, GVs with CMP, 1) are more sensitive to experimental pain stimuli, 2) exhibit exaggerated pain responses following acute exercise, 3) experience more muscle pain during acute exercise and 4) show augmented brain responses to both painful and non-painful experimental stimuli. These data suggest that some of the same pathophysiological mechanisms involved in FM may be maintaining chronic widespread muscle pain in GVs. Critical unanswered questions include whether promising treatments for CMP in GVs can affect laboratory measures of pain sensitivity and pain regulation and whether these changes relate to clinical improvements. We intend to begin to answer these questions by examining perceptual and brain hemodynamic responses to standardized painful stimuli and documenting their relationships to clinical outcomes before, during and upon completion of a viable, novel treatment for CMP.

There are no known efficacious treatments for GVs suffering CMP. Efficacy studies are needed to begin determining effective treatments for our Veterans following their service of our country. In FM, exercise training (both aerobic and resistance modes) is widely recognized as one of the few consistently efficacious treatments, resulting in improved well-being, increased physical function and in some cases decreased pain. One large scale treatment trial of aerobic exercise in GVs with chronic multi-symptom illness showed only modest improvements in pain, fatigue and mental health. We believe this trial had several limitations that greatly attenuated the treatment's effectiveness; consequently, it is premature to discount exercise training as a treatment for GVs with CMP. Further, we propose a novel approach that employs progressive resistance exercise training (RET) to treat GVs with CMP, while obtaining objective measures of nociceptive function, brain white matter tract pathways and total physical activity.

In addition to exercise performed as part of a structured training program, physical activity behaviors are important determinants of physical and mental health. Greater total physical activity levels are associated with increased physical function, improved mental health, increased energy and decreased symptoms of chronic pain. To our knowledge, none of the exercise training trials in FM have actually measured the impact of the exercise training on physical activity behaviors during daytime hours outside the intervention. It is plausible that the adoption of a structured exercise training program reduces physical activities performed during the rest of the day, and that this change in total physical activity could affect health outcomes. Objective measurement of physical activity will allow us to determine whether RET increases, decreases or has no impact on total physical activity levels in GVs with CMP. This will allow us to begin to characterize sub-groups who benefit the most from RET (e.g. potentially those GVs that maintain or increase their extra-intervention physical activity). Thus, in addition to supervised RET, we will objectively measure total physical activity levels outside of the intervention using accelerometers before, during and following treatment.

In summary, we propose to determine the efficacy of RET for the treatment of CMP and associated symptoms in GVs. In addition, we will assess the influence of RET on total physical activity, pain sensitivity and regulation, and brain white matter tracts. By applying functional neuroimaging techniques in conjunction with pain psychophysics we will test how the brains of Veterans with CMP respond to sensory stimuli and whether these responses can be modified by exercise training. We plan to use blood oxygen level dependent (BOLD) and diffusion tensor imaging (DTI) methods to evaluate the function of brain regions involved in pain processing and control and the microstructural properties of white matter tract pathways that connect these regions. In addition, we will determine the influence of RET on extra-intervention physical activity behaviors, testing a critical and unanswered question - whether total physical activity levels change as a result of engaging in a RET program in patients with CMP. The primary goals of this project will be accomplished by comparing GVs with CMP assigned to either RET or wait-list control (WLC) in a randomized controlled trial.

Study Type

Interventional

Enrollment (Actual)

77

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53705
        • William S. Middleton Memorial Veterans Hospital, Madison, WI

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Veteran of the Persian Gulf War
  • Chronic muscle pain

Exclusion Criteria:

  • Regular participation in resistance exercise
  • Color blindness
  • Claustrophobia
  • Medical conditions that could explain the Veteran's pain
  • Use of exclusionary drugs 3 weeks prior to testing
  • Major depressive disorder with melancholic features
  • Substance abuse
  • Schizophrenia
  • Bipolar disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm 1
Resistance exercise training
16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
No Intervention: Arm 2
Waitlist Control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short Form McGill Pain Questionnaire Visual Analog Scale (VAS).
Time Frame: 6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
The Short Form McGill Pain Questionnaire VAS ranges from 0 (No pain) to 100 (Worst possible pain). The respondent was asked to report how bad their pain has been over the past week. A higher score indicates a greater severity of pain.
6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
Physical Component Score (PCS) From the Veterans Rand 36 Item Heath Survey (VR-36).
Time Frame: 6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
The PCS is a composite summary score of items from the VR-36 related to physical health. Individual subscale scores are z transformed using US normative data, multiplied by a factor score coefficient, summed, and transformed to a T-score of a distribution (Mean = 50; Standard Deviation = 10). Higher scores represent better physical health.
6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
Patients' Global Impression of Change (PGIC).
Time Frame: 6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
The PGIC is a 7-item, self-report scale indicating the degree to which a patient has experienced any change since starting treatment. Each respondent was asked to rate "...the change (if any) in activity limitations, symptoms, emotions, and overall quality of life." related to their pain since beginning treatment. Scores range from 1, "No change (or condition has got worse)" to 7, "A great deal better, and a considerable improvement that has made all the difference." A higher score indicates greater improvement.
6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Activity (Accelerometer)
Time Frame: 6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
Physical activity is measured via accelerometer. The measure is a unit-less average of the number of counts per day. The higher the count, the greater the amount and intensity of physical activity accumulated over course of the day. Values range from 30,000 (sedentary) to 800,000 (highly active).
6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
Physical Activity (Self-report)
Time Frame: 6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
Total weekly self-reported physical activity was quantified using the International Physical Activity Questionnaire (IPAQ). The outcome is expressed as the number of metabolic equivalent (MET) minutes per week. One MET is defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml O2 per kg body weight x min, so 1 minute spent at rest is equal to 1 MET-minute. Respondents are only asked to report on physical activity of a light intensity or greater (≥3 METs, e.g., briskly walking). Higher values equal greater amount/intensity of activity.
6 weeks, 11 weeks, 17 weeks and 6 and 12 months post intervention.
Brain Structure: White Matter Tract Integrity, Operationalized With Fractional Anisotropy (FA) Measures at the Body of the Corpus Callosum.
Time Frame: 6 weeks, 11 weeks, 17 weeks and 6 and 12 months
Fractional anisotropy (FA) is a scalar value between 0 and 1 that describes the degree of anisotropy of a diffusion process. In the case of brain white matter integrity, it gives us an indication of the tract integrity at a particular region within the brain. 0 would indicate flow is completely unrestricted (no integrity), 1 that all flow is in the same direction (high integrity). In this instance we are using the FA at the body of the corpus callosum as an indicator of overall brain white matter integrity.
6 weeks, 11 weeks, 17 weeks and 6 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dane B. Cook, PhD, William S. Middleton Memorial Veterans Hospital, Madison, WI

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 16, 2013

Primary Completion (Actual)

June 18, 2019

Study Completion (Actual)

June 18, 2019

Study Registration Dates

First Submitted

May 5, 2011

First Submitted That Met QC Criteria

May 6, 2011

First Posted (Estimate)

May 9, 2011

Study Record Updates

Last Update Posted (Actual)

October 20, 2020

Last Update Submitted That Met QC Criteria

October 1, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • SPLD-004-10S

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Musculoskeletal Pain

Clinical Trials on Resistance Exercise Training

3
Subscribe